As one of the positive synergy effects, tumor antigen release by thermal ablation and monoclonal antibodies, targeting either the programmed cell death protein (PD-1) or its ligand PD-L1, can boost the immune response against cancer cells (Figure 1). The gene discussed is CD274; the disease is neoplasm.